Role of Phenotypes of Circulating Tumor Cells in the Diagnosis and Treatment of Colorectal Cancer

被引:10
|
作者
Zhong, Yuchen [1 ,2 ]
Ma, Tianyi [1 ]
Qiao, Tianyu [1 ]
Hu, Hanqing [1 ]
Li, Zhengliang [1 ]
Luo, Kangjia [1 ]
Wang, Yuliuming [1 ]
Tang, Qingchao [1 ]
Wang, Guiyu [1 ]
Huang, Rui [1 ]
Wang, Xishan [3 ]
机构
[1] Harbin Med Univ, Dept Colorectal Surg, Affiliated Hosp 2, Harbin 150080, Heilongjiang, Peoples R China
[2] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Colorectal Surg, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr,Dept Colorectal Surg, Beijing 100021, Peoples R China
来源
基金
中国国家自然科学基金; 黑龙江省自然科学基金;
关键词
circulating tumor cells; colorectal cancer; surgery; EMT; CLINICAL-SIGNIFICANCE; CHEMOTHERAPY; CAPTURE; BLOOD; LIVER; CTCS; EMT;
D O I
10.2147/CMAR.S316544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate the relationship between circulating tumor cells (CTCs) and their subpopulations and colorectal cancer (CRC). To explore the application of CTCs' numbers and positive rates in the diagnosis and treatment of CRC, and to assess the effect of surgery on CTCs numbers and positivity. Methods: We identified CTCs using the CanPatrol technique after enrollment. Peripheral blood samples were collected from 74 CRC patients before anti-tumor treatment. CTCs can be divided into the following three phenotypes: epithelial CTCs (E-CTCs) (EpCAM+, Vimentin-), mesenchymal CTCs (M-CTCs) (EpCAM-, Vimentin+), and mixed CTCs (E/ M-CTCs) (EpCAM+, Vimentin+). CTCs and the proportion of subtypes were statistically compared with clinicopathological characteristics. Results: The positive rate of M-CTCs was significantly higher in patients with tumor size >= 5 cm (85.7% vs 49.1%, P = 0.004) and carcinoembryonic antigen (CEA) >5 ng/mL (83.3% vs 51.0% p = 0.024). Moreover, the T stage (T1 0, T2 33.3%, T3 59.4%, T4 100%, p < 0.0005) and TNM stage (stage I 11.8%, stage II 79.2%, stage III 64.3%, stage IV 100%, p < 0.0005) were correlated with the positive rate of M-CTCs. We also found that the proportion of M-CTCs was correlated with the T stage (p < 0.0005) and TNM stage (p=0.0200), but not with the N stage (p=0.6889). In survival analysis, M-CTCs >1 were found associated with worse disease-free survival (p=0.007). After treatment, the number and proportion of CTCs and M-CTCs were significantly reduced. Conclusion: The positive rate of M-CTCs was associated with tumor size, T stage, TNM stage, vascular invasion, and CEA. As the disease progressed, the proportion of M-CTCs gradually increased, and the survival performance was worse in patients with a high positive rate of M-CTCs.
引用
收藏
页码:7077 / 7085
页数:9
相关论文
共 50 条
  • [41] Detection and clinical significance of circulating tumor cells in colorectal cancer
    Miao Jiang
    Shuiling Jin
    Jinming Han
    Tong Li
    Jianxiang Shi
    Qian Zhong
    Wen Li
    Wenxue Tang
    Qinqin Huang
    Hong Zong
    Biomarker Research, 9
  • [42] Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment
    Yang, Mei
    Zhang, Xiaotian
    Guo, Lixia
    Liu, Xiumin
    Wu, Jing
    Zhu, Hongquan
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [43] Circulating tumor cells - a new tool for optimizing diagnosis and treatment of breast cancer patients
    Fehm, Tanja
    Banys, Malgorzata
    13TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI) HELD JOINTLY WITH THE GERMAN SOCIETY OF OBSTETRICS & GYNECOLOGY, 2010, : 77 - 80
  • [44] Associations between the Epithelial-Mesenchymal Transition Phenotypes of Circulating Tumor Cells and the Clinicopathological Features of Patients with Colorectal Cancer
    Wu, Fengjie
    Zhu, Jun
    Mao, Yongjiang
    Li, Xiaomei
    Hu, Baoguang
    Zhang, Dianliang
    DISEASE MARKERS, 2017, 2017
  • [45] Independent Correlation Between Ki67 Index and Circulating Tumor Cells in the Diagnosis of Colorectal Cancer
    Yang, Yingchi
    Li, Jun
    Jin, Lan
    Wang, Dong
    Zhang, Jinghui
    Wang, Jin
    Zhao, Xiaomu
    Wu, Guocong
    Yao, Hongwei
    Zhang, Zhongtao
    ANTICANCER RESEARCH, 2017, 37 (08) : 4693 - 4700
  • [46] Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal Cancer
    Drevs, Joachim
    Malhotra, Mandeep singh
    Sahinbas, Huseyin
    Iliopoulos, Aggelos
    Beis, George
    Apostolou, Panagiotis
    Papasotiriou, Ioannis
    ANTICANCER RESEARCH, 2025, 45 (02) : 491 - 502
  • [47] KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer
    Kalikaki, Aristea
    Politaki, Helen
    Souglakos, John
    Apostolaki, Stella
    Papadimitraki, Elisavet
    Georgoulia, Nefeli
    Tzardi, Maria
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    Voutsina, Alexandra
    PLOS ONE, 2014, 9 (08):
  • [48] Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates
    Chedid, Julien
    Allam, Sabine
    Chamseddine, Nathalie
    Bou Zerdan, Maroun
    El Nakib, Clara
    Assi, Hazem, I
    SAGE OPEN MEDICINE, 2022, 10
  • [49] Role of circulating tumor cells and disseminated tumor cells in primary breast cancer
    Hayashi, Naoki
    Yamauchi, Hideko
    BREAST CANCER, 2012, 19 (02) : 110 - 117
  • [50] Role of circulating tumor cells and disseminated tumor cells in primary breast cancer
    Naoki Hayashi
    Hideko Yamauchi
    Breast Cancer, 2012, 19 : 110 - 117